journal of translational medicine 投稿经验
转化医学(英文)
！~医药科学专业解释：转化医学；转化医学就是希望将生物医学研究的关注点放在如何将实验室的研究发现转化导向为有利病人诊断、治疗方法的提高上。
2：网络释义：a--转化或转换医学（Translational Medicine）是近两三年来国际医学健康领域出现的新概念。
b--转译医学(Translational Medicine)c--转换医学（Translational Medicine），又叫转化医学是本世纪从循证医学发展而形成的一个医学实践和干预性流行病学的理念，它融汇基础科学、社会科学、政治科学于一体...d--阿斯利康中国创新中心(ICC)初期将着重进行癌症领域临床前到临床医学之间转化医学(translational medicine)的研究。
广义上讲，转化医学(转化科学)就是使病人直接受益的对基础科学研究的应用。
Open accessAll articles published by Journal of Translational Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.Authors of articles published in Journal of Translational Medicine are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.Article-processing chargesOpen access publishing is not without costs. Journal of Translational Medicine therefore levies an article-processing charge of £1250/$2005/€1560 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.Indexing servicesFollowing publication in Journal of Translational Medicine, the full-text of each article is deposited immediately and permanently archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories in e-Depot, the National Library of the Netherlands' digital archive of electronic publications. Journal of Translational Medicine is included in PubMed and all major bibliographic databases. A complete list of indexing web services that include BioMed Central's journals can be found here.Journal of Translational Medicine is tracked by Thomson Reuters (ISI)and has an Impact Factor of 3.47.Publication and peer review processAuthors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Translational Medicine, a personalized section of the site.Portability of peer reviewIn order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from Journal of Translational Medicine, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Journal of Translational Medicine and the authors choose to submit a revised version to another BioMed Central journal, we will pass the reviews on to the other journal's editors at the authors' request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another BioMed Central journal.ReprintsHigh-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.SupplementsJournal of Translational Medicine will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.Editorial policiesAny manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.Correspondence concerning articles published in Journal of Translational Medicine is encouraged. A 'post a comment' feature is available on all articles published by Journal of Translational Medicine. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.Editorial standardsBioMed Central is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.Ethical guidelinesSubmission of a manuscript to Journal of Translational Medicine implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.Journal of Translational Medicine's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.Standards of reportingJournal of Translational Medicine supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. Checklists are available for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), observational studies (STROBE), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). For authors of systematic reviews, an additional file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.Standardised gene nomenclature should be used throughout. Human gene symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database and any enquiries, or requests for new gene symbols, should be directed via email to hgnc@. Nomenclature committees for other species are listed at /about/faq#otherspecies. For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society.Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.Journal of Translational Medicine also supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform including the ISRCTN register administered by Current Controlled Trials, part of BioMed Central Group.The trial registration number should be included as the last line of the manuscript abstract. Data and materials releaseSubmission of a manuscript to Journal of Translational Medicine implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.Nucleotide sequencesNucleotide sequences can be deposited with the DNA Data Bank of Japan(DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).Protein sequencesProtein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).Mass spectrometryCompeting interestsJournal of Translational Medicine requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.Plagiarism detectionJournal of Translational Medicine's publisher, BioMed Central, is a member of the CrossCheck plagiarism detection initiative. In cases of suspected plagiarism CrossCheck is available to the editors of Journal of Translational Medicine to detect instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative allowing screening of published and submitted content for originality.Citing articles in Journal of Translational MedicineArticles in Journal of Translational Medicine should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.Article citations follow this format:Authors: Title. J Transl Med [year], [volume number]:[article number].e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Transl Med 2009, 1:115.refers to article 115 from Volume 1 of the journal.Why publish your article in Journal of Translational Medicine?High visibilityJournal of Translational Medicine's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.Speed of publicationJournal of Translational Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Translational Medicine, BioMed Central and PubMed Central and will also be included in PubMed.FlexibilityOnline publication in Journal of Translational Medicine gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).Promotion and press coverageArticles published in Journal of Translational Medicine are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Translational Medicine's pages and on the BioMed Central homepage.In addition, articles published in Journal of Translational Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Translational Medicine. A list of articles recently press-released by journals published by BioMed Central is available here.CopyrightAuthors of articles published in Journal of Translational Medicine retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).For further information about the advantages of publishing in a journal from BioMed Central, please click here..。
clinical and translational medicine审稿流程
clinical and translational medicine审稿流程【最新版】目录1.临床与转化医学概述2.临床与转化医学审稿流程介绍3.审稿流程的各个阶段4.审稿流程中作者与审稿人的角色5.审稿流程的优点与潜在问题6.总结正文一、临床与转化医学概述临床与转化医学（Clinical and Translational Medicine，简称 CTM）是一门关注从实验室到病床，再到社区应用的医学研究领域。
它的目标是加速医学研究成果的转化，以提高病患的诊断、治疗和预防水平。
在这个过程中，高效的审稿流程对推动研究成果的传播具有重要意义。
二、临床与转化医学审稿流程介绍临床与转化医学的审稿流程通常包括以下几个阶段：投稿、编辑初审、同行评议、作者修改、编辑终审和发表。
在这个过程中，作者和审稿人扮演着关键角色。
三、审稿流程的各个阶段1.投稿：作者将研究成果提交给期刊。
2.编辑初审：期刊编辑对投稿进行初步评估，判断是否符合期刊的发表要求和范围。
如果符合，编辑会邀请同行进行评审；如果不符合，编辑会退稿并给出理由。
3.同行评议：编辑选择具有相关专业知识和经验的审稿人对论文进行评审。
审稿人需在规定时间内完成评审，并提交评审意见。
4.作者修改：根据审稿人的意见，作者对论文进行修改。
如果审稿人要求重大修改，作者可能需要重新提交论文。
5.编辑终审：编辑对修改后的论文进行终审，确保论文质量符合期刊要求。
6.发表：通过终审的论文将被发表在期刊上。
四、审稿流程中作者与审稿人的角色1.作者：作者负责撰写论文，并在评审过程中根据审稿意见进行修改。
他们需要确保论文的质量和原创性，以提高论文被接受的可能性。
2.审稿人：审稿人负责对论文进行评审，提供专业意见和建议。
他们的角色对保证论文质量至关重要。
五、审稿流程的优点与潜在问题1.优点：审稿流程有助于确保论文的质量，提高研究的可靠性。
通过同行评审，论文可以得到专业的反馈和建议，有利于作者改进研究。
医学类外文期刊推荐信模板
尊敬的编辑：我写这封信是为了向您推荐一本医学类外文期刊，我相信这本期刊对于您的研究方向和领域将会是一份宝贵的资源。
这本期刊的名字是《XXX Journal of Medicine》，它是一本国际知名的医学期刊，涵盖了广泛的医学领域，如临床医学、基础医学、预防医学等。
首先，我要强调的是，《XXX Journal of Medicine》的编辑团队非常专业和高效。
他们对于稿件的审查非常严格，只接受高质量的研究成果。
我曾经有一次机会向该期刊投稿，我深刻地体会到了编辑团队的严谨和专业。
他们对我的稿件进行了细致的审查，并提供了许多有建设性的反馈意见，这使得我的研究论文得到了很大的改进。
其次，这本期刊的影响因子非常高，它在医学领域的影响力不容忽视。
影响因子是衡量期刊学术水平的的重要指标之一，高影响因子的期刊意味着它发表的研究成果受到了广泛的认可和关注。
作为一位医学研究者，发表在这本期刊上的研究成果将会在学术界产生重要的影响，提升您的学术声誉和影响力。
此外，《XXX Journal of Medicine》的读者群体也非常广泛。
它拥有一大批全球范围内的医学专业人士和学者，包括医生、研究员、教授等。
发表在这本期刊上的研究成果将会被广大读者所阅读和引用，这对于您研究成果的传播和影响力的提升将起到积极的推动作用。
最后，我想提醒您的是，《XXX Journal of Medicine》的投稿和审稿过程非常透明和公正。
他们会为每篇投稿提供一个唯一的编号，并告知您审稿的时间周期。
在整个审稿过程中，您将会清楚地了解审稿人的意见和反馈，这有助于您对研究论文进行进一步的修改和完善。
总之，我强烈推荐您将《XXX Journal of Medicine》作为您研究成果发表的首选期刊。
这本期刊的专业编辑团队、高影响因子、广泛的读者群体以及公正透明的审稿过程将会为您的研究成果提供最好的展示平台。
我相信这本期刊将会为您的研究事业带来重要的推动和帮助。
英国医学杂志之论文写作经验与投稿指南【编辑吐血推荐】
英国医学杂志中文版BMJ CHINESE EDITION（论文写作与投稿经验）科学论文的讨论需要结构化与结构式摘要相似The case for structuring the discussion of scientific papersMuch the same as that for structuring abstractsMichael Docherty Professor of rheumatologyCity Hospital, Nottingham NG5 1PBRichard Smith Editor, BMJ在写作中，结构安排最难，写小说、剧本、诗歌、政府报告或科学论文，莫不如此。
如果结构恰到好处，其它就容易多了；而且，无论哪一种精巧的语言都掩饰不了结构上的缺陷。
结构的重要性在于读者不会迷失方向。
读者该知道从何起，到何处，再去何方。
好结构使读者得益，知道从何处获取特殊信息，并能吸纳全部重要信息。
医学刊物的读者对论文的IMRaD结构（引言、方法、结果和讨论；Introduction,Methods ,Results and Discussion）1相当稔熟，自觉或不自觉地都知道每部分的作用。
同样，读者也已熟悉结构式摘要，它所含的信息比非结构式摘要多2，3。
有些刊物要求特殊论文使用特殊结构，如报告随机试验（randomised trials）的论文使用CONSORT结构4。
现在我们提议，科学论文的讨论部分也要结构化，因为它经常是论文最薄弱之处，仔细地解释而成为喋喋不休5。
老式论文往往缺少新的数据资料（可能包括病例报告），讨论却洋洋洒洒。
讨论的作用似乎是让读者相信，作者对数据的阐述及推测的正确。
这不是对证据的公正检验。
时代变了，人们更重视方法和结果，因为方法愈加复杂，更具科学价值。
但是，我们仍然发现许多论文的讨论似乎是在“推销”自已。
Lancet主编Richard Horton 和一些人士曾撰文谈及作者如何在论文的讨论中玩弄辞藻6，7。
british journal of pharmacology 投稿经验
british journal of pharmacology 投稿经验（原创实用版）目录1.介绍《英国药理学杂志》的基本信息2.分析投稿流程和注意事项3.探讨投稿经验和心得4.总结并给出建议正文《英国药理学杂志》（British Journal of Pharmacology）是一本享有盛誉的国际学术期刊，主要关注药理学和药物研究的最新进展。
该杂志为药理学领域的研究者提供了一个展示研究成果和交流学术观点的平台。
在准备向该杂志投稿之前，了解其投稿流程、注意事项以及一些投稿经验和心得是非常有帮助的。
投稿流程和注意事项：1.投稿前，请确保您的研究成果符合该杂志的投稿范围和要求。
您可以通过阅读官方网站上的“作者须知”和“投稿指南”来了解详细信息。
2.在投稿之前，建议您对自己的研究成果进行充分的检查和修改，确保文章质量。
同时，遵循期刊的格式要求，以提高稿件的接受率。
3.在投稿过程中，您需要注册一个账户并按照系统提示填写相关信息。
提交完成后，您将收到一封确认邮件，其中包含您的投稿编号。
4.通常情况下，投稿后会经过同行评审的过程。
根据评审意见，编辑会决定是否接受您的文章。
您可以在投稿系统中查看审稿进度和审稿意见。
投稿经验和心得：1.提前做好准备工作，了解期刊的投稿要求和审稿流程，可以提高投稿的成功率。
2.确保您的文章结构清晰，观点明确，论据充分。
在文章中引用相关文献以支持您的观点，并注意避免抄袭。
3.在投稿过程中，保持与编辑和审稿人的良好沟通。
对于审稿意见，要认真对待并给予充分的回应。
4.耐心等待审稿结果，不要过于焦虑。
如果稿件被拒，不要气馁，总结经验教训，改进文章并尝试其他期刊。
总结和建议：向《英国药理学杂志》投稿是一个严谨的过程，需要您做好充分的准备。
在投稿过程中，遵循投稿要求和注意事项，保持良好的沟通和耐心等待。
希望以上内容能对您的投稿有所帮助。
如何向外文期刊投稿
如何向外文期刊投稿论文投稿注意事项国外科学界有一句名言：一项科学实验，直到其成果发表并被理解才算完成。
此名言阐述了两个道理，首先是研究成果必须发表，即信息得到传播和交流；其次是发表的论文必须被读者接受并理解，即信息被社会认可，产生了应有的社会效益和经济效益。
据《美国医学会杂志》（Journal of the American Medical Association , JAMA）统计：1996JAMA 国际投稿占全部自由来稿的13%，接受率仅为（国际投稿的）8%，其中英国投稿53篇，接受9篇；澳大利亚投稿20篇，接受3篇；加拿大投稿109篇，接受19篇；……中国仅投稿4篇，接受0篇。
1997JAMA国际投稿占全部自由来稿的14%，接受率为9%，其中英国投稿33篇，接受4篇；澳大利亚投稿16篇，接受1篇；加拿大投稿100篇，接受19篇；……中国仅投稿6篇，接受0篇。
以上数据从一个侧面表明，虽然目前我国生物医学工作者正在进行或已经完成了大量的国际水平的研究工作，但与西方国家比较，其成果向国外生物医学期刊投稿的比率仍很低，刊用率则更低。
其主要原因除了与我国生物医学工作者英文论文写作水平有关外；还与我国大多数生物医学工作者不了解国外生物医学期刊的编辑政策和标准、不了解向国外生物医学期刊投稿的程序，以致不敢向国外投稿或所投稿件不符合国外生物医学期刊的要求有很大关系。
为了使我国生物医学工作者能在国外生物医学期刊，尤其是在国际著名期刊上发表更多的高水平论文，使其它国家的生物医学科学家更多、更好地了解中国，提高我国在国际生物医学领域的地位，我国生物医学工作者应努力提高自己的英文写作技能、认真学习国外生物医学期刊编排的国际标准、熟悉国外生物医学期刊论文的发表过程，并了解如何获得国外生物医学期刊编辑的帮助。
正确选择期刊据估计，目前西方国家有几千种英文生物医学期刊；而国际著名生物医学期刊自由来稿的退稿率均在90%左右。
刘建勋研究生导师简介
刘建勋研究生导师简介刘建勋，河北衡水人，1955年3月24日出生，博士，研究员，博士生导师。
1978年毕业于天津南开大学生物系中草药（药理药化）专业，2004年获日本药科大学博士，中国中医科学院首席研究员，973项目首席科学家。
发表学术论文400余篇，SCI收录50余篇，出版学术专著14部，主编2部，副主编5部，编委7部；获国内外发明专利11项；获各类科研成果奖16项，第一完成人14项，其它2项，其中国家科技进步奖一等奖1项、二等奖1项，省部级科技成果奖一等奖4项，二等奖8项，三等奖2项；1996年被评为“全国中青年医学科技之星”，2002年被评为入选“卫生部有突出贡献中青年专家”，2004年获得国务院颁发的政府特殊津贴，2016年获得“全国优秀科技工作者”称号。
主要研究方向:中药药理与中药新药研发。
1、主要社会兼职情况国家药典委员会委员、中国中药协会医院与企业药事管理委员会主任委员,中国药理学会理事及中药药理专业委员会副主任委员、中华中医药学会实验药理学分会副主任委员、中国动物学会中医药动物专业委员会副秘书长。
北京及国家药品监督管理局项目审评专家。
2、近5年来主持科研项目情况1)国家重点基础研究计划973课题: 基于病证结合的气血相关理论研究(2015CB554400), 2015.1-2019.8, 750万元, 首席科学家2)国家自然基金课题:AMPK介导的细胞自噬炎性反应信号通路对痰瘀互结证AS的调控机制及化痰祛瘀解毒方药的干预作用 (81573650), 2016.1-2019.12, 73.2万元，主持人3)中国中医科学院院级课题: 中药复方祛瘀化痰通脉功效与评价, 2015.1-2016.12,40万元，主持人4)北京市科技计划“十病十药”研发课题：祛瘀化痰通脉颗粒的临床前研究(Z131100002513006)， 2013.4-2015.4， 110万，主持人5)重大新药创制课题：朝向国际注册的治疗血管性痴呆有效组分配伍新药维脑康胶囊的临床前研究(2012ZX10004301-608)， 2012.1-2015.12, 390万元,主持人6)国家自然基金课题：动脉粥样硬化易损斑块形成及化痰祛瘀解毒方的干预作用（81073085）， 2011.1-2014.12，33万，主持人3、近年来发表有代表性学术论文、专著或教材（限5篇）1．Jianxun Liu*, Hua Zhu, Yongqiu Zheng, Zhaobin Xu, Lei Li, Tao Tan, Ki Ho Park, Jincai Hou Cuixiang Zhang, Dan Li, Ran Li, Zhenguo Liu, NoahWeisleder, Desheng Zhu, Peihui Lin , Jianjie Ma. cardioprotection of recombinant human mg53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2015,80:10–19.2．Cuixiang Zhang, TianLan, JincaiHou, Juan Li, Rende Fang, Zhicheng Yang, Min Zhang, Jianxun Liu*, and Bing Liu.NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget. 2014, 5: 4392-4405.3．Yanyan Bao, Chengren Lin, Junguo Ren, Jianxun Liu*. MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3K p110d). Apoptosis, 2013,18(3):260-70.4．Xiaodi Fan Jun Wang, Jincai Hou, Chengren Lin, Alan Bensoussan, Dennis Chang, Jianxun Liu*,and Bing Wang. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway/Journal of Translational Medicine， 2015, 13(1):1-115．刘建勋主编《病证结合动物模型拟临床研究思路与方法》，人民卫生出版社，2014年4、近年来获省级以上奖励情况1)2014年，源于中医临床的中药药效学评价体系的构建与应用，国家科学技术进步奖，二等奖，第一完成人2)2014年，中药复方功效研究与评价体系的构建及应用，北京市科学技术奖，一等奖，第一完成人3)2013年，中药复方指征药效物质基础的研究，中华中医药学会科学技术奖，一等奖，第一完成人4)2012年，病证结合动物模型拟临床研究方法的建立与应用，中华中医药学会科学技术奖，一等奖，第一完成人5)2011年，治疗缺血性脑损伤及神经退行性病变中药药效学评价的方法学研究，北京市科学技术奖，二等奖，第一完成人6)2009年，中国药学会，中国药学发展奖突出成就奖，个人奖7)2009年，中华中医药学会，李时珍医药创新奖，个人奖5、指导研究生情况自2000年开始担任中国中医科学院博士研究生导师，先后培养博士后15人，博士20余人，硕士30余人。
international journal of surgery 投稿难度 经验分享
international journal of surgery 投稿难度经验分享
国际外科期刊的投稿难度会因各种因素而有所不同。
以下是一些经验分享，希望能对你有所帮助：
1. 提前了解期刊要求：在投稿之前，一定要仔细阅读并了解目标期刊的投稿要求，包括投稿类型、格式要求、字数限制、引用格式等。
遵循这些要求能够提高被接受的机会。
2. 选择合适的期刊：要选择一个与你的研究方向相关的期刊。
在投稿前，先浏览一下该期刊已发表的文章，了解期刊的领域和研究重点。
如果你的研究内容与该期刊的主题相符，被接受的机会更高。
3. 重要性和创新性：期刊编辑通常更喜欢具有重要性和创新性的研究。
确保你的研究内容在国际上有重要性，并且具有一定的创新性。
4. 投稿文件准备：在投稿之前，确保你的研究论文准备充分。
这包括仔细检查你的写作、语法和拼写错误，确保研究方法和结果的清晰和准确。
5. 良好的结构和逻辑：确保你的论文有良好的结构和逻辑。
在介绍中引入你的研究问题和背景，清晰地呈现你的方法和结果，并对你的研究进行讨论和结论。
6. 遵循道德和伦理规范：在研究过程中，必须遵守科学研究的道德和伦理规范。
确保你的研究获得了相应的伦理审查，并在
论文中明确说明。
7. 审稿意见回应：如果你的论文被拒稿并要求进行修改后再投，一定要认真阅读审稿意见，并对其中的问题进行认真回复和修改。
最重要的是要保持积极的态度和耐心。
在国际外科期刊投稿的过程中，可能会面临拒稿和修改的情况。
重要的是不要灰心，根据审稿人的意见进行改进，并继续努力。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
journal of translational medicine 投稿
经验
Journal of Translational Medicine is an open-access, international, peer-reviewed scientific publication that aims to provide researchers with innovative research and improvements in terms of patient care. The journal covers a wide range of topics, including molecular biology, oncology, neuroscience, pharmacology, epidemiology, and many others. As a novice writer and researcher, I recently submitted an
article to the Journal of Translational Medicine, and in this article, I will share my experience and the steps I took to submit my article.
The first step I took was to visit the journal's website and familiarize myself with the submission guidelines. The website of the journal is user-friendly, and it is easy to navigate through the different sections. After reading through the submission guidelines, I decided to prepare my manuscript according to the journal's format, which is well documented on the website.
The next step was to select the appropriate category for my article. The Journal of Translational Medicine has various categories to submit articles to, such as review articles, research articles, case reports, and methodological articles.
I chose the research article category as it suited the objective of my research.
After selecting the category, I prepared my manuscript according to the journal's specific guidelines. The
guidelines cover aspects such as the format, structure, and style of the manuscript. I paid special attention to the abstract, which should provide concise and clear information about the objective of the study, the methods used, and the main findings.
After completing my manuscript, I uploaded it together with the required documents such as the cover letter, consent form, and conflicts of interest form. I then selected the appropriate editors and reviewers who I believed would provide suitable feedback on my manuscript.
The last step was to patiently wait for the response from the Journal of Translational Medicine. The review process can take some time, and it is essential to remain patient and not get discouraged. After a few weeks, I received the reviews with constructive criticism and suggestions on how to improve the manuscript.
In conclusion, the submission process for the Journal of Translational Medicine is easy and straightforward. The journal's website provides detailed information and guidelines, making it easy for researchers to prepare and submit their manuscripts. The review process is rigorous, but it is an essential step in ensuring quality research and innovation in patient care. I learned a lot of valuable lessons during the submission process, and I am grateful for the opportunity to contribute to the journal.。